Adenosine 5′-triphosphate infusions reduced disease activity and inflammation in a patient with active rheumatoid arthritis

Rheumatology

Volumn 49, Issue 11, 2010, Pages 2223-2225

  Bours, Martijn J L ^a   Peeters, Ralph H R M ^b   Landewé, Robert B M ^a   Beijer, Sandra ^a   Arts, Ilja C W ^a   Dagnelie, Pieter C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FOLIC ACID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ADENOSINE 5'-PHOSPHOROTHIOATE; ADENOSINE PHOSPHATE; ADENOSINE PHOSPHOROTHIOATE; ANTIRHEUMATIC AGENT; DRUG DERIVATIVE; NUCLEOTIDE;

ADULT; ANTIINFLAMMATORY ACTIVITY; CASE REPORT; CORRELATION ANALYSIS; DISEASE ACTIVITY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IN VIVO STUDY; INFLAMMATION; LETTER; MAXIMUM TOLERATED DOSE; PAIN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; DAILY LIFE ACTIVITY; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED;

ACTIVITIES OF DAILY LIVING; ADENOSINE MONOPHOSPHATE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 78649371696     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq177     Document Type: Letter

References (10)

1. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate. Implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65: 168-73.
2. Di Virgilio F, Boeynaems J-M, Robson SC. Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol 2009;9:507-13.
3. Swennen ELR, Bast A, Dagnelie PC. Immunoregulatory effects of adenosine 5′-triphosphate on cytokine release from stimulated whole blood. Eur J Immunol 2005;35: 852-8.
4. Swennen ELR, Bast A, Dagnelie PC. Purinergic receptors involved in the immunomodulatory effects of ATP in human blood. Biochem Biophys Res Commun 2006;348: 1194-9.
5. Swennen ELR, Coolen EJCM, Arts ICW, Bast A, Dagnelie PC. Time-dependent effects of ATP and its degradation products on inflammatory markers in human blood ex vivo. Immunobiology 2008; 213:389-97.
6. Dagnelie PC, Agteresch HJ. Promising effects of adenosine triphosphate infusion on nutritional status and quality of life in advanced non-small-cell lung cancer: a randomized clinical trial. Drug Dev Res 2003;59: 146-51.
7. Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:321-8.
8. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007;27:793-806.
9. Beijer S, Wijckmans NE, van Rossum E et al. Treatment adherence and patients' acceptance of home infusions with adenosine 5′-triphosphate (ATP) in palliative home care. Support Care Cancer 2008;16:1419-24.
10. Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005;23: S93-9.